Gene | Association with increased prostate cancer risk | Association with other cancer risk (eg, breast, ovary, colon, uterus) and management options | Prevalence of germline mutations in metastatic prostate cancer | Prevalence of germline mutations in prostate cancer with family history | Treatment implications in metastatic prostate cancer | |
Eligible for DNA-damaging agents: PARP inhibitor, platinum | Eligible for immunotherapy: PD-1 inhibitor | |||||
ATM | X | X | 1.6% | 2.0% | X | |
BARD1 | X | |||||
BRCA1 | X | X | 0.9% | 0.7% | XX | |
BRCA2 | X | X | 5.4% | 4.7% | XX | |
BRIP1 | X | |||||
CDK12 | X | |||||
CHEK1 | X | |||||
CHEK2 | X | X | 1.9% | 2.9% | X | |
FANCL | X | |||||
HOXB13 | X | Not evaluated | 1.1% | |||
MLH1 | X | X | 0.1% | X | ||
MSH2 | X | X | 0.1% | 0.7% | X | |
MSH6 | X | X | 0.1% | 0.5% | X | |
NBN | X | 0.3% | 0.3% | X | ||
PALB2 | X | 0.4% | 0.6% | X | ||
PMS2 | X | X | 0.3% | 0.5% | X | |
RAD51B | X | |||||
RAD51C | X | 0.1% | 0.2% | X | ||
RAD51D | X | 0.4% | 0.2% | X | ||
RAD54L | X |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟